These cut-off values improved selectivity in controls to some extent (true-negatives: SCA3/SCA6/FRDA controls: 83/79/90%), and sensitivity in particular in SCA3 and FRDA patients (true-positives: SCA3/SCA6/FRDA patients: 63/64/40%). This evidence concerns the gene ATXN3 and Friedreich ataxia.